Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-15 + Taxotere in Hormone Refractory Prostate Carcinoma
NCT00031187Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Oct 2000
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SGN-15 in prostate cancer (PCa) (2 arms), sponsored by Seagen Inc. Started Oct 2000; status: completed.
02
Drugs
SGN-15
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00031187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031187.